STOCK TITAN

[Form 4] Tourmaline Bio, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Tourmaline Bio (TRML) disclosed a Form 4 showing a director made a charitable gift of company stock. On 10/24/2025, the director donated 5,000 shares of common stock (transaction code G) at $0, classified as a gift to a donor‑advised fund for charitable purposes.

Following the transaction, the director beneficially owns 88,281 shares, held directly.

Tourmaline Bio (TRML) ha comunicato una Modulo 4 che mostra che un direttore ha fatto un regalo di beneficenza di azioni dell'azienda. Il 24/10/2025, il direttore ha donato 5.000 azioni di azioni ordinarie (codice di transazione G) a $0, classificato come un dono a un fondo con donazione consigliata per scopi di beneficenza.

Dopo la transazione, il direttore detiene beneficiariamente 88.281 azioni, detenute direttamente.

Tourmaline Bio (TRML) divulgó un Formulario 4 que muestra que un director hizo un dono caritativo de acciones de la empresa. El 24/10/2025, el director donó 5,000 acciones de acciones ordinarias (código de transacción G) por $0, clasificado como un don para un fondo asesorado por donantes con fines caritativos.

Después de la transacción, el director posee de forma beneficiosa 88,281 acciones, manteniéndolas directamente.

Tourmaline Bio (TRML)은 이사 한 사람이 회사 주식의 자선 선물을 했다라는 Form 4를 공개했다. 2025년 10월 24일, 이사 5,000주를 기부의 주식(거래 코드 G)을 $0로 기부했고, 이는 자선 목적의 기부자 보조 기금에 대한 기부로 분류된다.

거래 후, 이사는 실질적으로 88,281주를 보유하며, 직접 보유 중이다.

Tourmaline Bio (TRML) a divulgué un Formulaire 4 montrant qu'un administrateur a fait un don de actions de l'entreprise à des fins caritatives. Le 24/10/2025, l'administrateur a fait don de 5 000 actions d'actions ordinaires (code de transaction G) pour 0 $, classé comme un don à un fonds géré par des donateurs pour des buts caritatifs.

Suite à la transaction, l'administrateur détient bénéficiairement 88 281 actions, détenues directement.

Tourmaline Bio (TRML) hat ein Form 4 offengelegt, das zeigt, dass ein Direktor eine wohltätige Schenkung von Firmaktien gemacht hat. Am 24.10.2025 hat der Direktor 5.000 Aktien Stammaktien (Transaktionscode G) zu 0 $ gespendet, klassifiziert als Spende an einen Donor-Advised-Fonds für wohltätige Zwecke.

Nach der Transaktion besitzt der Direktor Beneficial 88.281 Aktien, direkt gehalten.

Tourmaline Bio (TRML) كشفت عن نموذج 4 يُظهر أن مديراً قد قدم هدية خيرية من أسهم الشركة. في 24/10/2025، قام المدير بالتبرع بـ 5,000 سهم من الأسهم العادية (رمز المعاملة G) مقابل $0، مصنّف كهدية إلى صندوق موجه من المتبرعين لغرض خيري.

بعد الصفقة، يملك المدير بشكل مستفاد 88,281 سهم، مُحتفظاً بها بشكل مباشر.

Positive
  • None.
Negative
  • None.

Tourmaline Bio (TRML) ha comunicato una Modulo 4 che mostra che un direttore ha fatto un regalo di beneficenza di azioni dell'azienda. Il 24/10/2025, il direttore ha donato 5.000 azioni di azioni ordinarie (codice di transazione G) a $0, classificato come un dono a un fondo con donazione consigliata per scopi di beneficenza.

Dopo la transazione, il direttore detiene beneficiariamente 88.281 azioni, detenute direttamente.

Tourmaline Bio (TRML) divulgó un Formulario 4 que muestra que un director hizo un dono caritativo de acciones de la empresa. El 24/10/2025, el director donó 5,000 acciones de acciones ordinarias (código de transacción G) por $0, clasificado como un don para un fondo asesorado por donantes con fines caritativos.

Después de la transacción, el director posee de forma beneficiosa 88,281 acciones, manteniéndolas directamente.

Tourmaline Bio (TRML)은 이사 한 사람이 회사 주식의 자선 선물을 했다라는 Form 4를 공개했다. 2025년 10월 24일, 이사 5,000주를 기부의 주식(거래 코드 G)을 $0로 기부했고, 이는 자선 목적의 기부자 보조 기금에 대한 기부로 분류된다.

거래 후, 이사는 실질적으로 88,281주를 보유하며, 직접 보유 중이다.

Tourmaline Bio (TRML) a divulgué un Formulaire 4 montrant qu'un administrateur a fait un don de actions de l'entreprise à des fins caritatives. Le 24/10/2025, l'administrateur a fait don de 5 000 actions d'actions ordinaires (code de transaction G) pour 0 $, classé comme un don à un fonds géré par des donateurs pour des buts caritatifs.

Suite à la transaction, l'administrateur détient bénéficiairement 88 281 actions, détenues directement.

Tourmaline Bio (TRML) hat ein Form 4 offengelegt, das zeigt, dass ein Direktor eine wohltätige Schenkung von Firmaktien gemacht hat. Am 24.10.2025 hat der Direktor 5.000 Aktien Stammaktien (Transaktionscode G) zu 0 $ gespendet, klassifiziert als Spende an einen Donor-Advised-Fonds für wohltätige Zwecke.

Nach der Transaktion besitzt der Direktor Beneficial 88.281 Aktien, direkt gehalten.

Tourmaline Bio (TRML) كشفت عن نموذج 4 يُظهر أن مديراً قد قدم هدية خيرية من أسهم الشركة. في 24/10/2025، قام المدير بالتبرع بـ 5,000 سهم من الأسهم العادية (رمز المعاملة G) مقابل $0، مصنّف كهدية إلى صندوق موجه من المتبرعين لغرض خيري.

بعد الصفقة، يملك المدير بشكل مستفاد 88,281 سهم، مُحتفظاً بها بشكل مباشر.

Tourmaline Bio (TRML) 披露了一份 Form 4,显示一位董事作出公司股票的慈善捐赠。2025年10月24日,该董事 捐赠了5,000股普通股(交易代码 G),金额为 $0,被归类为对慈善目的的捐赠给一个捐赠者建议的基金(donor-advised fund)。

交易结束后,该董事 实际持有88,281股股份,直接持有。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KANTOFF AARON

(Last) (First) (Middle)
C/O TOURMALINE BIO, INC.
27 WEST 24TH STREET, SUITE 702

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tourmaline Bio, Inc. [ TRML ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/24/2025 G(1) 5,000 D $0 88,281 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares donated to a donor-advised fund, which will use the gifted shares for charitable purposes.
/s/ Brad Middlekauff, Attorney-in-Fact 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tourmaline Bio (TRML) report?

A director reported a gift of 5,000 common shares on 10/24/2025 (transaction code G).

What does transaction code G indicate on a Form 4 for TRML?

Code G indicates a gift of securities; the filing states the shares were donated to a donor‑advised fund.

How many TRML shares does the director own after the gift?

The director beneficially owns 88,281 shares following the reported transaction, held directly.

Was there a sale price for the TRML shares gifted?

No. The reported price is $0 because it was a gift, not a sale.

Does this Form 4 indicate use of a Rule 10b5-1 plan?

The excerpt does not indicate that this transaction was made under a Rule 10b5‑1(c) plan.
Tourmaline Bio

NASDAQ:TRML

TRML Rankings

TRML Latest News

TRML Latest SEC Filings

TRML Stock Data

1.23B
21.73M
22.06%
89.92%
10.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK